WO2008013988A3 - Method of treating a condition associated with phosphorylation of task-1 - Google Patents

Method of treating a condition associated with phosphorylation of task-1 Download PDF

Info

Publication number
WO2008013988A3
WO2008013988A3 PCT/US2007/016999 US2007016999W WO2008013988A3 WO 2008013988 A3 WO2008013988 A3 WO 2008013988A3 US 2007016999 W US2007016999 W US 2007016999W WO 2008013988 A3 WO2008013988 A3 WO 2008013988A3
Authority
WO
WIPO (PCT)
Prior art keywords
task
phosphorylation
treating
condition associated
subject
Prior art date
Application number
PCT/US2007/016999
Other languages
French (fr)
Other versions
WO2008013988A9 (en
WO2008013988A2 (en
Inventor
Steven J Feinmark
Richard B Robinson
Original Assignee
Univ Columbia
Steven J Feinmark
Richard B Robinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/029544 external-priority patent/WO2007014347A2/en
Priority claimed from US11/498,343 external-priority patent/US8097650B2/en
Application filed by Univ Columbia, Steven J Feinmark, Richard B Robinson filed Critical Univ Columbia
Priority to EP07836321A priority Critical patent/EP2068628A4/en
Publication of WO2008013988A2 publication Critical patent/WO2008013988A2/en
Publication of WO2008013988A9 publication Critical patent/WO2008013988A9/en
Publication of WO2008013988A3 publication Critical patent/WO2008013988A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides methods and compositions for treating a condition associated with phosphorylation of TASK-I in a subject comprising administering to the subject an amount of an agent effective to overcome the phosphorylation dependent loss of TASK-I function so as to thereby treat the condition. In a specific embodiment of the invention the agent is a TREK-I agonist.
PCT/US2007/016999 2006-07-27 2007-07-27 Method of treating a condition associated with phosphorylation of task-1 WO2008013988A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07836321A EP2068628A4 (en) 2006-07-27 2007-07-27 Method of treating a condition associated with phosphorylation of task-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2006/029544 WO2007014347A2 (en) 2005-07-27 2006-07-27 Method of treating a condition associated with phosphorylation of task-1
USPCT/US2006/029544 2006-07-27
US11/498,343 US8097650B2 (en) 2005-07-27 2006-08-02 Method of treating a condition associated with phosphorylation of TASK-1
US11/498,343 2006-08-02

Publications (3)

Publication Number Publication Date
WO2008013988A2 WO2008013988A2 (en) 2008-01-31
WO2008013988A9 WO2008013988A9 (en) 2008-04-10
WO2008013988A3 true WO2008013988A3 (en) 2008-12-18

Family

ID=38982134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016999 WO2008013988A2 (en) 2006-07-27 2007-07-27 Method of treating a condition associated with phosphorylation of task-1

Country Status (2)

Country Link
EP (1) EP2068628A4 (en)
WO (1) WO2008013988A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028485A1 (en) * 1998-01-27 2002-03-07 Meadows Helen Jane Novel compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097798A1 (en) * 2000-06-16 2001-12-27 Smithkline Beecham Corporation Method for the prevention or reduction of cardiovascular events associated with coronary intervention
DE10332685A1 (en) * 2003-07-18 2005-02-17 Bayer Healthcare Ag Use of a modulator of specific potassium channels, expressed preferentially in the atrium, for treatment and prevention of arrhythmia, coronary disease and hypertension
CA2617057A1 (en) * 2005-07-27 2007-02-01 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of task-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028485A1 (en) * 1998-01-27 2002-03-07 Meadows Helen Jane Novel compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMIN ET AL.: "Cross-talk between the mechano-gated K2p channel TREK-1 and the actin cytoskeleton", EMBO J., vol. 24, no. 1, January 2005 (2005-01-01), pages 44 - 53, XP008103203 *
NINIO ET AL.: "Dietary Fish Oil Protects Against Stretch-Induced Vulnerability to Atrial Fibrillation in a Rabbit Model", JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, vol. 16, no. 11, May 2005 (2005-05-01), pages 1189 - 1194, XP008103200 *
See also references of EP2068628A4 *

Also Published As

Publication number Publication date
WO2008013988A9 (en) 2008-04-10
EP2068628A4 (en) 2009-11-04
EP2068628A2 (en) 2009-06-17
WO2008013988A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2007089445A3 (en) Ang2 and vegf inhibitor combinations
WO2008124675A3 (en) Methods of controlling algae with thaxtomin and thaxtomin compositions
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2006105527A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2009089494A3 (en) Pharmaceutical compositions
WO2008089201A3 (en) Heterocyclic-substituted piperidine as orl-1 ligands
WO2011047341A3 (en) Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
WO2008019372A3 (en) 2-aminobenzoxazole carboxamides as 5ht3 modulators
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
WO2009133374A3 (en) Antisapstain compositions comprising a haloalkynyl compound, an azole and an unsaturated acid
ZA200807802B (en) Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2010017368A3 (en) Methods and compositions for treating anxiety
WO2010027863A3 (en) Potentiated biocidal compositions and methods of use
WO2007014347A3 (en) Method of treating a condition associated with phosphorylation of task-1
GB0619262D0 (en) Compositions and methods for treating skin conditions
GB0601950D0 (en) Compositions and methods of treating diabetes
WO2007147868A3 (en) Prevention of muscle atrophy
WO2008051793A3 (en) Method of preventing or treating metabolic syndrome
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836321

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009521861

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007836321

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

NENP Non-entry into the national phase

Ref country code: JP